8 May 2018 - - San Diego, California-based developer of therapies for antibiotic-resistant infections using bacteriophage-based technology AmpliPhi Biosciences Corp. (NYSE MKT: APHB) will utilise the Therapeutic Development Services funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to conduct further preclinical studies of AB-SA01, the company said.
The Therapeutic Development Services program funds the provision of preclinical services for selected companies and researchers in order to advance development of promising interventional agents.
AB-SA01 is a 3-phage investigational therapeutic being developed for treatment of serious and drug-resistant Staphylococcus aureus (S. aureus) infections. In preclinical studies, AB-SA01 demonstrated broad activity against more than 96% of global S. aureus clinical isolates, including multidrug-resistant forms.
AB-SA01 has completed two Phase 1 studies and has also been administered to patients under compassionate use guidelines in the US and Australia for treatment of serious and life-threatening S. aureus infections.
AmpliPhi Biosciences is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology.
Its lead product candidates target multidrug-resistant S. aureus and P. aeruginosa, which are included on the WHO's 2017 Priority Pathogens List.